Targeting MYC/HDAC2 interaction in Group 3 medulloblastoma – rationales for an innovative therapeutic approach

Introduction: Medulloblastoma (MB) is one of the most frequent malignant brain tumors in children. Four subgroups with different molecular characteristics as well as differing clinical courses have been identified. In patients with Group 3 MBs overall survival remains particularly poor despite multimodal treatment. Group 3 and Group 4 tumors are characterized by modifications of their chromatin organizing machinery. We here explore the interaction of transcription factor MYC as a driving force in Group 3 MB and the chromatin modifying class I histone deacetylases (HDACs). Methods: Expression of class I HDACs in…